AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Epithelial membrane protein 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P54851

UPID:

EMP2_HUMAN

Alternative names:

Protein XMP

Alternative UPACC:

P54851; B2R7V6; D3DUF8

Background:

Epithelial membrane protein 2 (EMP2), also known as Protein XMP, plays a crucial role in regulating cell membrane composition, influencing processes such as cell migration, proliferation, and adhesion. It is involved in the regulation of protein surface expression, including adhesion markers and lipid rafts, and negatively regulates caveolae formation. EMP2 also affects the surface expression of MHC1 and ICAM1, modulating T-cell mediated cytotoxicity, and plays a role in angiogenesis and embryonic development.

Therapeutic significance:

EMP2's involvement in Nephrotic syndrome 10, characterized by severe proteinuria and progressive renal failure, highlights its potential as a therapeutic target. Understanding EMP2's role could open doors to novel strategies for managing this condition and possibly other related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.